The Adjuvant Effect of Rapamycin for a New Multi-stage Subunit Vaccine Candidate LT69

• 作 者: HongxiaNiu;ChunxiangBai;BingdongZhu;
• 机 构: Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology & Gansu Provincial Key
• 出 处: 中国免疫学会第十届全国免疫学学术大会
• 发表日期: 2015年期

　　Objective: Tuberculosis (TB) remains a major global health problem and ranks as the second leading cause of death from an infectious disease worldwide.Mycobacterium bovis Bacillus Calmette-Gue is the only tuberculosis vaccine for human use in current, but its protective efficacy wanes significantly over a period of 10-15 years or less.